Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials

Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.